« Glucagon-like Peptide Receptor Agonists (GLP-1 receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients with Type 2 Diabetes Mellitus », Can Diabetes Endocrinol Today, vol. 2, nᵒ 3, p. 33–37, nov. 2024, doi: 10.58931/cdet.2024.2333.